Literature DB >> 28503929

Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque.

Mauricio A Martins1, Damien C Tully2, Young C Shin1, Lucas Gonzalez-Nieto1, Kim L Weisgrau3, David J Bean2, Rujuta Gadgil2, Martin J Gutman1, Aline Domingues1, Helen S Maxwell1, Diogo M Magnani1, Michael Ricciardi1, Nuria Pedreño-Lopez1, Varian Bailey1, Michael A Cruz1, Noemia S Lima4, Myrna C Bonaldo4, John D Altman5, Eva Rakasz3, Saverio Capuano3, Keith A Reimann6, Michael Piatak7, Jeffrey D Lifson7, Ronald C Desrosiers1, Todd M Allen2, David I Watkins1.   

Abstract

Effector memory T cell (TEM) responses display potent antiviral properties and have been linked to stringent control of simian immunodeficiency virus (SIV) replication. Since recurrent antigen stimulation drives the differentiation of CD8+ T cells toward the TEM phenotype, in this study we incorporated a persistent herpesviral vector into a heterologous prime/boost/boost vaccine approach to maximize the induction of TEM responses. This new regimen resulted in CD8+ TEM-biased responses in four rhesus macaques, three of which controlled viral replication to <1,000 viral RNA copies/ml of plasma for more than 6 months after infection with SIVmac239. Over the course of this study, we made a series of interesting observations in one of these successful controller animals. Indeed, in vivo elimination of CD8αβ+ T cells using a new CD8β-depleting antibody did not abrogate virologic control in this monkey. Only after its CD8α+ lymphocytes were depleted did SIV rebound, suggesting that CD8αα+ but not CD8αβ+ cells were controlling viral replication. By 2 weeks postinfection (PI), the only SIV sequences that could be detected in this animal harbored a small in-frame deletion in nef affecting six amino acids. Deep sequencing of the SIVmac239 challenge stock revealed no evidence of this polymorphism. However, sequencing of the rebound virus following CD8α depletion at week 38.4 PI again revealed only the six-amino acid deletion in nef. While any role for immunological pressure on the selection of this deleted variant remains uncertain, our data provide anecdotal evidence that control of SIV replication can be maintained without an intact CD8αβ+ T cell compartment.

Entities:  

Keywords:  HIV/AIDS; SIV vaccine; lymphocyte depletion; nonhuman primate

Mesh:

Substances:

Year:  2017        PMID: 28503929      PMCID: PMC5564033          DOI: 10.1089/AID.2017.0046

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  83 in total

Review 1.  Starting at the beginning: new perspectives on the biology of mucosal T cells.

Authors:  Hilde Cheroutre
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 2.  Poxvirus vector-based HIV vaccines.

Authors:  Giuseppe Pantaleo; Mariano Esteban; Bertram Jacobs; Jim Tartaglia
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

3.  CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection.

Authors:  R Keith Reeves; Jacqueline Gillis; Fay E Wong; Yi Yu; Michelle Connole; R Paul Johnson
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

4.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

5.  Expression, purification, and functional analysis of murine ectodomain fragments of CD8alphaalpha and CD8alphabeta dimers.

Authors:  P Kern; R E Hussey; R Spoerl; E L Reinherz; H C Chang
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

6.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  De novo assembly of highly diverse viral populations.

Authors:  Xiao Yang; Patrick Charlebois; Sante Gnerre; Matthew G Coole; Niall J Lennon; Joshua Z Levin; James Qu; Elizabeth M Ryan; Michael C Zody; Matthew R Henn
Journal:  BMC Genomics       Date:  2012-09-13       Impact factor: 3.969

9.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

10.  Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

Authors:  Florian Klein; Lilian Nogueira; Yoshiaki Nishimura; Ganesh Phad; Anthony P West; Ariel Halper-Stromberg; Joshua A Horwitz; Anna Gazumyan; Cassie Liu; Thomas R Eisenreich; Clara Lehmann; Gerd Fätkenheuer; Constance Williams; Masashi Shingai; Malcolm A Martin; Pamela J Bjorkman; Michael S Seaman; Susan Zolla-Pazner; Gunilla B Karlsson Hedestam; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2014-11-10       Impact factor: 14.307

View more
  9 in total

1.  A Recombinant Rhesus Monkey Rhadinovirus Deleted of Glycoprotein L Establishes Persistent Infection of Rhesus Macaques and Elicits Conventional T Cell Responses.

Authors:  Alexander S Hahn; Georg F Bischof; Anna K Großkopf; Young C Shin; Aline Domingues; Lucas Gonzalez-Nieto; Eva G Rakasz; David I Watkins; Armin Ensser; Mauricio A Martins; Ronald C Desrosiers
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

2.  Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.

Authors:  Mauricio A Martins; Damien C Tully; Núria Pedreño-Lopez; Benjamin von Bredow; Matthias G Pauthner; Young C Shin; Maoli Yuan; Noemia S Lima; David J Bean; Lucas Gonzalez-Nieto; Aline Domingues; Martin J Gutman; Helen S Maxwell; Diogo M Magnani; Michael J Ricciardi; Varian K Bailey; John D Altman; Dennis R Burton; Keisuke Ejima; David B Allison; David T Evans; Eva G Rakasz; Christopher L Parks; Myrna C Bonaldo; Saverio Capuano; Jeffrey D Lifson; Ronald C Desrosiers; Todd M Allen; David I Watkins
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

3.  The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in Mamu-B*08+ Rhesus Macaques.

Authors:  Mauricio A Martins; Lucas Gonzalez-Nieto; Young C Shin; Aline Domingues; Martin J Gutman; Helen S Maxwell; Diogo M Magnani; Michael J Ricciardi; Núria Pedreño-Lopez; Varian K Bailey; John D Altman; Christopher L Parks; David B Allison; Keisuke Ejima; Eva G Rakasz; Saverio Capuano; Ronald C Desrosiers; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

4.  CD8β Depletion Does Not Prevent Control of Viral Replication or Protection from Challenge in Macaques Chronically Infected with a Live Attenuated Simian Immunodeficiency Virus.

Authors:  Matthew S Sutton; Amy Ellis-Connell; Alexis J Balgeman; Gabrielle Barry; Andrea M Weiler; Scott J Hetzel; Yan Zhou; Annie W Lau-Kilby; Rosemarie D Mason; Kristin K Biris; John R Mascola; Nancy J Sullivan; Mario Roederer; Thomas C Friedrich; Shelby L O'Connor
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

5.  Recombinant Herpesvirus Vectors: Durable Immune Responses and Durable Protection against Simian Immunodeficiency Virus SIVmac239 Acquisition.

Authors:  Isabelle M Castro; Michael J Ricciardi; Lucas Gonzalez-Nieto; Eva G Rakasz; Jeffrey D Lifson; Ronald C Desrosiers; David I Watkins; Mauricio A Martins
Journal:  J Virol       Date:  2021-06-24       Impact factor: 5.103

6.  Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques.

Authors:  Julia B McBrien; Andrew K H Wong; Erick White; Diane G Carnathan; John H Lee; Jeffrey T Safrit; Thomas H Vanderford; Mirko Paiardini; Ann Chahroudi; Guido Silvestri
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

7.  Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques.

Authors:  Nuria Pedreño-Lopez; Brandon C Rosen; Walter J Flores; Matthew J Gorman; Thomas B Voigt; Michael J Ricciardi; Kristin Crosno; Kim L Weisgrau; Christopher L Parks; Jeffrey D Lifson; Galit Alter; Eva G Rakasz; Diogo M Magnani; Mauricio A Martins; David I Watkins
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 8.786

Review 8.  New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.

Authors:  Katherine M Bricker; Ann Chahroudi; Maud Mavigner
Journal:  Viruses       Date:  2021-08-06       Impact factor: 5.048

9.  Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies.

Authors:  Nuria Pedreño-Lopez; Christine M Dang; Brandon C Rosen; Michael J Ricciardi; Varian K Bailey; Martin J Gutman; Lucas Gonzalez-Nieto; Matthias G Pauthner; Khoa Le; Ge Song; Raiees Andrabi; Kim L Weisgrau; Nicholas Pomplun; José M Martinez-Navio; Sebastian P Fuchs; Jens Wrammert; Eva G Rakasz; Jeffrey D Lifson; Mauricio A Martins; Dennis R Burton; David I Watkins; Diogo M Magnani
Journal:  Mol Ther Methods Clin Dev       Date:  2020-02-13       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.